“Acambis and Arrow to Work Together on Novel Vaccines”

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

Arrow Therapeutics and Acambis have agreed to collaborate on research on novel vaccines. Initial studies will include an assessment by Acambis of Arrow's Transposon Mediated Differential Hybridization target discovery technology, which will be used to identify attenuating genes and surface proteins for a potential vaccine to be used against a pathogen of Acambis' choosing. “Arrow's technology represents an extremely powerful approach to the development of new vaccines against some major bacterial infections” and will complement “Acambis' strategy to meet major unmet medical needs and commercial opportunities with live, attenuated vaccine products,” said Acambis Chief Scientific Officer Thomas Monath.

Return to Vaccination News Home Page

DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.